NeurAxis (NRXS) Competitors $2.47 +0.14 (+6.01%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$2.42 -0.05 (-2.02%) As of 08/22/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXS vs. TELA, SPAI, LUNG, QTI, PYPD, EDAP, SRTS, MDAI, DXR, and ICCMShould you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include TELA Bio (TELA), Safe Pro Group (SPAI), Pulmonx (LUNG), QT Imaging (QTI), PolyPid (PYPD), EDAP TMS (EDAP), Sensus Healthcare (SRTS), Spectral AI (MDAI), Daxor (DXR), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry. NeurAxis vs. Its Competitors TELA Bio Safe Pro Group Pulmonx QT Imaging PolyPid EDAP TMS Sensus Healthcare Spectral AI Daxor IceCure Medical TELA Bio (NASDAQ:TELA) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment. Do insiders & institutionals hold more shares of TELA or NRXS? 94.4% of TELA Bio shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 4.7% of TELA Bio shares are owned by company insiders. Comparatively, 26.4% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate TELA or NRXS? TELA Bio presently has a consensus target price of $4.50, suggesting a potential upside of 154.24%. NeurAxis has a consensus target price of $7.00, suggesting a potential upside of 183.40%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than TELA Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TELA Bio 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, TELA or NRXS? TELA Bio has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500. Which has stronger earnings & valuation, TELA or NRXS? NeurAxis has lower revenue, but higher earnings than TELA Bio. NeurAxis is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTELA Bio$69.30M1.01-$37.84M-$1.12-1.58NeurAxis$3.22M5.54-$14.63M-$0.99-2.49 Does the media prefer TELA or NRXS? In the previous week, TELA Bio and TELA Bio both had 1 articles in the media. TELA Bio's average media sentiment score of 1.30 beat NeurAxis' score of -0.01 indicating that TELA Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TELA Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeurAxis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TELA or NRXS more profitable? TELA Bio has a net margin of -54.12% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat TELA Bio's return on equity.Company Net Margins Return on Equity Return on Assets TELA Bio-54.12% -329.48% -57.34% NeurAxis -492.76%N/A -641.25% SummaryNeurAxis beats TELA Bio on 9 of the 14 factors compared between the two stocks. Get NeurAxis News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXS vs. The Competition Export to ExcelMetricNeurAxisElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.81M$39.56M$5.76B$9.58BDividend YieldN/AN/A4.41%4.10%P/E Ratio-1.343.4131.1026.05Price / Sales5.54250.60432.51103.82Price / CashN/A41.3637.7358.48Price / Book-9.152.259.536.61Net Income-$14.63M-$2.66M$3.26B$265.56M7 Day Performance2.49%3.58%2.10%1.97%1 Month Performance-10.51%10.42%2.81%-0.36%1 Year Performance-23.29%141.59%30.56%19.03% NeurAxis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXSNeurAxis2.4842 of 5 stars$2.47+6.0%$7.00+183.4%-20.8%$16.81M$3.22M-1.3419TELATELA Bio3.0194 of 5 stars$1.74+2.4%$4.50+158.6%-38.5%$67.35M$69.30M-1.55120High Trading VolumeSPAISafe Pro Group0.9695 of 5 stars$3.78-6.9%$8.00+111.6%N/A$65.64M$2.17M0.0011News CoverageLUNGPulmonx3.9357 of 5 stars$1.53-4.4%$7.66+400.9%-75.4%$65.19M$83.79M-1.07250QTIQT ImagingN/A$2.12+4.4%N/A+330.8%$57.52M$4.00M0.00N/APYPDPolyPid2.6753 of 5 stars$3.53+0.6%$12.40+251.3%+1.2%$55.80MN/A-0.9280EDAPEDAP TMS3.0227 of 5 stars$1.48+0.3%$8.50+474.3%-67.0%$55.15M$69.18M-2.39230News CoverageUpcoming EarningsGap DownSRTSSensus Healthcare1.9467 of 5 stars$3.20-3.3%$8.00+150.0%-52.1%$54.42M$41.81M-53.3340News CoverageMDAISpectral AI3.2433 of 5 stars$2.11-0.5%$3.50+65.9%+36.6%$53.67M$29.58M-3.0683Gap UpDXRDaxor4.2723 of 5 stars$10.41-5.5%$25.00+140.2%+31.3%$53.30MN/A0.0037Gap DownICCMIceCure Medical1.9146 of 5 stars$0.86-3.6%$2.39+177.3%+27.1%$52.38M$3.29M-5.3860 Related Companies and Tools Related Companies TELA Bio Alternatives Safe Pro Group Alternatives Pulmonx Alternatives QT Imaging Alternatives PolyPid Alternatives EDAP TMS Alternatives Sensus Healthcare Alternatives Spectral AI Alternatives Daxor Alternatives IceCure Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access